Please try another search
Apellis Pharmaceuticals Inc. (APLS) announced results from a five-year analysis of its GALE extension study showing that SYFOVRE delayed geographic atrophy lesion growth by approximately 1.5 years...
Investing.com - Apellis Pharma (NASDAQ: APLS) reported second quarter EPS of $-0.33, $0.15 better than the analyst estimate of $-0.48. Revenue for the quarter came in at $178.49M versus the...
Investing.com - Apellis Pharma (NASDAQ: APLS) reported third quarter EPS of $1.67, $0.12 better than the analyst estimate of $1.55. Revenue for the quarter came in at $458.6M versus the consensus...
Instrument Type
Region
Sector
Industry
Date
Category
Provider